Technical Reports on Biotech Equities -- Teligent, VIVUS, Kadmon, and Intrexon

Tuesday, October 24, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 24, 2017 /PRNewswire/ --

If you want a Stock Review on TLGT, VVUS, KDMN, or XON then come over

to and sign up for your free customized report. While Biotechnology and Pharmaceutical companies both produce medicine, biotechnology companies' medicines have a biological basis, and pharmaceutical companies'
medicines have a chemical basis. This morning, revisits the Biotech space, focusing on the most recent performance of the following equities: Teligent Inc. (NASDAQ: TLGT), VIVUS Inc. (NASDAQ: VVUS), Kadmon Holdings Inc. (NYSE: KDMN), and Intrexon Corp. (NYSE: XON). Learn more about these stocks by downloading their comprehensive and free reports from member's area at:


On Monday, shares in Buena, New Jersey-based Teligent Inc. saw a decline of 3.41%, ending the day at $6.24. The stock recorded a trading volume of 333,766 shares. The Company's shares are trading below their 50-day moving average by 7.20%. Moreover, shares of Teligent, which develops, manufactures, and markets topical formulations in the US, have a Relative Strength Index (RSI) of 33.11.

On October 02nd, 2017, Teligent announced that it has received approval of its partnered abbreviated new drug application from the US FDA of Desonide Lotion, 0.05%. This product was submitted under a partnered development agreement by the Company with Impax Labs, Inc. This is Teligent's first approval received under this agreement. Based on recent QuintilesIMS Health data from July 2017, the total addressable market for this product is approximately $22.6 million. TLGT complete research report is just a click away at:


Shares in Campbell, California headquartered VIVUS Inc. ended the day 2.58% lower at $0.77 with a total trading volume of 631,474 shares. The stock is trading below its 50-day moving average by 17.08%. Shares of the Company, which develops and commercializes therapies to address unmet medical needs in the US and the European Union, have an RSI of 26.67. The complimentary report on VVUS can be downloaded at:

Kadmon Holdings 

At the close of trading on Monday, shares in New York headquartered Kadmon Holdings Inc. finished 0.87% lower at $3.43 with a total trading volume of 129,404 shares. The stock has advanced 26.10% over the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 13.18% and 6.09%, respectively. Additionally, shares of Kadmon, which discovers, develops, and commercializes small molecules and biologics to address unmet medical needs, have an RSI of 52.52.  

On October 06th, 2017, Kadmon announced that the US FDA has granted orphan drug designation to KD025, its Rho-associated coiled-coil kinase inhibitor for the treatment of chronic graft-versus-host disease (cGVHD), a serious complication following allogeneic bone marrow or stem cell transplantation. KD025 is being studied in an ongoing Phase-2 clinical trial in adults with steroid-dependent or steroid-refractory cGVHD and active disease. Sign up for your complimentary research report on KDMN at:


Germantown, Maryland-based Intrexon Corp.'s shares recorded a trading volume of 1.07 million shares at the end of yesterday's session, which was above their three months average volume of 915,840 shares. The stock closed the day 2.85% lower at $17.37. The Company's shares are trading below their 50-day moving average by 7.84%. Additionally, shares of Intrexon, which operates in the synthetic biology field in the US, have an RSI of 34.93.

On October 16th, 2017, Intrexon announced the achievement of a key milestone in the development of its innovative solution for control of the agricultural pest fall armyworm (Spodoptera frugiperda) in collaboration with a leading agricultural company. Intrexon Crop Protection's targeted, biologically-based approach utilizing Oxitec's self-limiting insect technology holds substantial promise to control this major agricultural pest and prevent widespread crop losses, thereby benefitting farmers and enhancing food sustainability. Get free access to your research report on XON at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store